Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease

World J Gastroenterol. 2007 Sep 14;13(34):4610-4. doi: 10.3748/wjg.v13.i34.4610.

Abstract

Aim: To investigate the role of gastric mucosa at the secretion of sTREM-1 in peptic ulcer.

Methods: Seventy two patients were enrolled; 35 with duodenal, 21 with gastric ulcer and 16 with chronic gastritis. Patients were endoscoped and gastric juice was aspirated. Patients with duodenal and gastric ulcer underwent a second endoscopy post-treatment. Biopsies were incubated in the absence/presence of endotoxins or gastric juice. Supernatants were collected and sTREM-1 and TNFalpha were measured by enzyme immunoabsorbent assays. Scoring of gastritis was performed before and after treatment according to updated Sydney score.

Results: Patients with duodenal and gastric ulcer and those with chronic gastritis had similar scores of gastritis. sTREM-1 was higher in supernatants of tissue samples of H pylori-positive than of H pylori-negative patients with gastric ulcer. Median (+/- SE) sTREM-1 was found increased in supernatants of patients with gastric ulcer before treatment (203.21 +/- 88.91 pg/1000 cells) compared to supernatants either from the same patients post-treatment (8.23 +/- 5.79 pg/1000 cells) or from patients with chronic gastritis (6.21 +/- 0.71 pg/1000 cells) (P < 0.001 and < 0.001, respectively). Similar differences for sTREM-1 were recorded among LPS-stimulated tissue samples of patients (P = 0.001). Similar differences were not found for TNFalpha. Positive correlations were found between sTREM-1 of supernatants from patients with both duodenal and gastric ulcer before treatment and the degree of infiltration of neutrophils and monocytes.

Conclusion: sTREM-1 secreted by the gastric mucosa is an independent mechanism connected to the pathogenesis of peptic ulcer. sTREM-1 was released at the presence of H pylori from the inflamed gastric mucosa in the field of gastric ulcer.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Amoxicillin / administration & dosage
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Ulcer Agents / administration & dosage
  • Chronic Disease
  • Clarithromycin / administration & dosage
  • Drug Administration Schedule
  • Duodenal Ulcer / drug therapy
  • Duodenal Ulcer / etiology
  • Duodenal Ulcer / metabolism*
  • Duodenal Ulcer / microbiology
  • Duodenal Ulcer / pathology
  • Endoscopy, Gastrointestinal
  • Female
  • Gastric Juice / metabolism
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism*
  • Gastric Mucosa / microbiology
  • Gastric Mucosa / pathology
  • Gastritis / complications
  • Gastritis / drug therapy
  • Gastritis / metabolism*
  • Gastritis / microbiology
  • Gastritis / pathology
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / metabolism*
  • Helicobacter Infections / microbiology
  • Helicobacter Infections / pathology
  • Helicobacter pylori / isolation & purification
  • Humans
  • Lipopolysaccharides / pharmacology
  • Male
  • Membrane Glycoproteins / metabolism*
  • Middle Aged
  • Omeprazole / administration & dosage
  • Receptors, Immunologic
  • Severity of Illness Index
  • Stomach Ulcer / drug therapy
  • Stomach Ulcer / etiology
  • Stomach Ulcer / metabolism*
  • Stomach Ulcer / microbiology
  • Stomach Ulcer / pathology
  • Tissue Culture Techniques
  • Triggering Receptor Expressed on Myeloid Cells-1
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Lipopolysaccharides
  • Membrane Glycoproteins
  • Receptors, Immunologic
  • TREM1 protein, human
  • Triggering Receptor Expressed on Myeloid Cells-1
  • Tumor Necrosis Factor-alpha
  • Amoxicillin
  • Clarithromycin
  • Omeprazole